Background: Second-generation antipsychotics (SGAs) are thought to have a lower likelihood of inducing extrapyramidal symptoms (EPS) than are first-generation antipsychotics (FGAs). Clinical ...

Oct. 2, 2003 — Olanzapine was associated with the fewest patients with extrapyramidal symptoms (EPS) at six months compared with baseline, according to the results of a large prospective trial ...

Credit: Getty Images. Extrapyramidal symptoms that developed in patients with schizophrenia after initiation of treatment with atypical antipsychotic agents were associated with increased healthcare ...

This study presents a meta-analysis of the influence of several potentially biasing factors (eg industry support, extrapyramidal side effects) on efficacy of studies comparing second-generation ...

New research illuminates the benefits and risks of antipsychotic medication in children and its impact on individual well-being, social, educational and/or vocational functioning, and disease burden.

The FDA has notified healthcare professionals that it has updated the Pregnancy section of the labeling for the entire class of antipsychotic drugs. The new drug labeling now provides additional ...

This case highlights vitamin E’s potential as an effective adjunct treatment for patients with antipsychotic-induced motor symptoms resistant to standard therapies. Vitamin E has shown significant ...

The introduction of atypical antipsychotics represents an advance in the treatment of schizophrenia because they are generally better tolerated than conventional antipsychotics and have been ...

Antipsychotic drugs are used to treat symptoms of psychiatric disorders, such as bipolar disorder and schizophrenia. The new labeling standards are for older antipsychotic drugs as well as newer ones.

Alzheimer’s Death Rate Steadily Increasing; FDA Offers New Guidance Atypical antipsychotics are known to improve many of the symptoms experienced by elderly patients who exhibit neuropsychiatric ...